Division of Biology and Medicine
Legorreta Cancer Center

Remembering Alex Brodsky, Ph.D.

In November, we lost a treasured member of our research community, Dr. Alex Brodsky. With his passing, we’re reminded of the importance of our cancer research mission. His colleagues have composed a message in his honor.

 

Alex Brodsky, PhD

It is with great sadness that we announce the passing of our colleague, collaborator and friend, Alexander S. Brodsky, PhD. Alex was an Associate Professor in the Department of Pathology and Laboratory Medicine, and had been a valued faculty member of the Legorreta Cancer Center. 

Alex began his scientific career in RNA biology. He completed undergraduate studies at the University of Pennsylvania before moving to MIT for graduate work, where his PhD focused on solving RNA structures by NMR. Alex expanded the scope of his expertise to the field of genomics during his postdoctoral training at the Dana Farber Cancer Institute. There he elucidated fundamental mechanisms of RNA export from the nucleus to the cytoplasm, leveraging early genomic technologies to produce a body of published work funded by Ruth L. Kirschstein and NIH fellowship awards. 

Alex joined the Brown faculty in 2005, first in the Department of Molecular Biology, Cell Biology and Biochemistry and later the Department of Pathology and Laboratory Medicine at Rhode Island Hospital. He was a longtime affiliate of the Center for Computational Molecular Biology and the Brown Center for Genomics and Proteomics. As a lab head Alex was generous with his time, and thrived in his role of mentor to his students, technicians and postdoctoral trainees. 

As an investigator at Brown, Alex's interests pivoted to cancer research, in particular using computational approaches to understand the remodeling of extracellular matrix composition that supports tumor growth. It is a tragic irony that Alex would contract the aggressive brain cancer glioblastoma, a topic he pursued with collaborators at the Legorreta Cancer Center. In the wake of his passing, we are reminded of the need for effective treatments for glioblastoma which Alex sought to advance. We are inspired with renewed determination to make a positive impact to the outcomes of patients so profoundly burdened by this disease. 

Over the last two years Alex and his devoted wife Adina made the most of their time together, traveling with family between treatments and packing in every moment of happiness in the days remaining. Alex was fully engaged in science to the end, marked by spirited reviews of new data and several recent publications. While his loss leaves an undeniable void, Alex also leaves a living legacy of curiosity in the minds of his many students, colleagues and friends. 

Paul Bertone, PhD, Associate Professor of Medicine

Sean Lawler, PhD, Associate Professor of Pathology and Laboratory Medicine 

 

I first met Alex Brodsky almost 20 years ago for a get-to-know-each-other in the backyard of his home in Cambridgeport  south of central square near memorial drive.  Searching through my memory I am sometimes let down by my failure to recall  important things while remembering weird little details of the same event.  We met with our families. I think I brought my kids. For some reason I remember giant perfectly rendered cubes of yellow and orange cheese on a plate that I imagine were transferred fresh out the  Bread and Circus/Whole Foods cling wrap moments before we arrived.  I believe there was a dog running around.  Finally, and most importantly, I remember my strong first impression of Alex as a confident, ambitious scientist.  Intense and focused, he had just finished his postdoc with Pam Silver at the Dana Farber and was ready to conquer the world. Both he and I came from a background in chemistry but he pursued this at MIT with a PhD in an NMR lab which I found impressive.  He talked about how to implement his experiments with formaldehyde crosslinking and immunoprecipitation on thousands of genes at a time.  It was an exciting time to work in biology. The sequence of the human genome had been published. Cambridge was an exciting place.  What seemed impossible last week was happening just down the street in Kendall square or Longwood.  

 

We both were recruited to Brown to the MCB department by John Sedivy in 2005 and moved into adjoining labs on the fourth floor of 70 Ship street. Thinking about the direction and a good setup for our new labs, we strategized on buying equipment together. Alex had ambitious plans for large scale science keeping step with the genomic revolution that was happening just north of us in Boston.  He was a determined scientist and mentor, often working one-on-one with his first graduate student Michael Bronson.  I remember his struggles with the problematic technology of tiling arrays, troubleshooting technical problems that stood in the way of discovery. Ultimately sequencing took over as the preferred tool and continuing the  work on arrays seemed more and more like throwing good money after bad. These are the inevitable frustrations of the ambitious. However, Alex’s persistence got him back to the business of discovery. He published more than 50 papers in the field of cancer biology. Alex left a big impression on his students through his mentorship and lectures in Advanced Biochemistry. Alex collaborated with numerous scientists to solve scientific problems.  Throughout his career, he was a prolific scholar delivering many talks at scientific meetings and conferences. 

 

I don’t know anybody who had a deeper knowledge of scientific literature in the field of genomics. He was an expert in genomics and I was not alone in asking him how the latest ‘seq’ technology worked.  He worked collaboratively with others in MCB providing invaluable technical assistance to other research groups. Away from work, I remember talking about our love for soccer and sharing funny family stories. There were ups and downs in his life but throughout he was a devoted father and a scholar. Both of us moved from our labs in the old Ship street building and we saw less and less of each other.  I will miss the impromptu coffees, lunches and kvetch sessions we shared over those 9 years we worked together. 

Will Fairbrother, PhD. Professor of Molecular Biology, Cell Biology and Biochemistry
 
 
Alex Brodsky was a good friend and one of the smartest people I’ve ever met and worked with during my scientific career. We worked together on the 4th floor of Ship St. for eight years often discussing the challenges of life as a junior faculty member, publishing, but mostly strategizing over grant applications and funding. In addition to our friendship, Alex and I jointly extended our scientific interests in gene expression towards how it might be deregulated in ovarian cancer. And although we were both big fans of genomics, Alex was the expert in using genome-wide techniques and its associated data analyses. As I arrived at Brown a few years before Alex, I introduced Alex to Laurent Brard, an ovarian cancer researcher and clinician at Women and Infants Hospital of Rhode Island. Laurent and Alex worked very closely and published five papers together on genomic discovery in ovarian cancer. Alex was one of the first scientists to use modern genomic tools to address key aspects of ovarian cancer mortality. He also began to pursue more clinical studies on developing novel therapeutic strategies for ovarian cancer. Alex and I also published two papers on ovarian development and cancer together. In both cases, Alex helped us connect our mechanistic work with human clinical data that greatly elevated the importance of our work. What struck me about these experiences was the ease at which Alex was not only able to process clinical data but also how quickly he could construct meaningful outcomes from them. Soon after these joint papers were published, Alex moved to Rhode Island Hospital where he continued this journey and extended his expertise towards colon and brain cancer. For several years, we met regularly for coffee and lunch until the Covid-19 pandemic. Alex’s impact on cancer research lives on at Brown as there are now several labs using an immunocompetent mouse ID8 model of high-grade serous ovarian cancer that he identified and helped bring to Brown.  
 
Richard Freiman, PhD. Professor of Molecular Biology, Cell Biology and Biochemistry